Objective: To describe neuroglycopenia as a specific syndrome caused by insufficient glucose availability during brain development.

Design: Neurologic examinations, neuropsychologic tests, biochemical methods, and functional imaging.

Participants: Patients afflicted by genetic mutation of the cerebral glucose transporter type 1 and a patient afflicted by persistent infantile hypoglycemia (hyperinsulinism) matched to her healthy twin.

Results: The hallmark of the phenotype is the combination of infantile epilepsy and cerebellar and pyramidal tract dysfunction, together with permanent neuropsychologic abnormalities and reduced thalamocortical glucose uptake despite subsequent supply of energetic substrate.

Conclusions: When neuroglycopenia-the lack of adequate glucose supply to the nervous system-occurs in the developing brain, thalamic and cortical metabolism mature aberrantly, causing epilepsy associated with other characteristic neurologic and behavioral disturbances, a pattern also reflected in functional images, as if there were a temporal window during which glucose were crucial for brain development. When maturation is complete, glucose merely serves as a fuel, and then, when deficient, it only causes unrelated disturbances.

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneur.64.4.noc60165DOI Listing

Publication Analysis

Top Keywords

glucose supply
8
glucose
6
brain
4
brain glucose
4
supply syndrome
4
syndrome infantile
4
infantile neuroglycopenia
4
neuroglycopenia objective
4
objective describe
4
describe neuroglycopenia
4

Similar Publications

Obesity and retinal microvasculature dysfunction are linked and impact visual acuity. The aim of this study was to determine the relationship between the HOMA-IR score and the presence of vascular dysfunction (capillary perfusion and flux index) of the optic nerve head (ONH) of the retina in obese patients and to determine its diagnostic performance to predict vascular dysfunction. A case-control study was conducted in 2022 involving individuals from obese and non-obese groups.

View Article and Find Full Text PDF

Engineered extracellular vesicles as "supply vehicles" to alleviate type 1 diabetes.

Extracell Vesicles Circ Nucl Acids

November 2024

The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523059, Guangdong, China.

Recent findings have indicated that the deficiency of inhibitory programmed cell death ligand 1 (PD-L1) and galectin-9 (Gal-9) in pancreatic β-cells is associated with the progression of type 1 diabetes (T1D). This suggests that exogenous PD-L1 and Gal-9 may have promising potential as therapeutics for the treatment of T1D. In light of these reports, a recent work investigated the potential of artificial extracellular vesicles (aEVs) with the presentation of PD-L1 and Gal-9 ligands (PD-L1-Gal-9 aEVs) as a treatment for T1D, with the findings published in .

View Article and Find Full Text PDF

Background: One method for noninvasive and simple urinary microalbumin testing is urine test strips. However, when visually assessing urine test strips, accurate assessment may be difficult due to environmental influences-such as lighting color and intensity-and the physical and psychological influences of the assessor. These complicate the formation of an objective assessment.

View Article and Find Full Text PDF

Enhancing Cannabichromenic Acid Biosynthesis in .

ACS Synth Biol

January 2025

State Key Laboratory of Fine Chemicals, Frontiers Science Centre for Smart Materials Oriented Chemical Engineering, School of Bioengineering, Dalian University of Technology, Dalian 116024, China.

Cannabichromene (CBC), a valuable but extremely low-abundance component of cannabinoids in L., is known for its ability to promote neurogenesis. The scarcity of CBC in natural is primarily attributed to the inefficiency of the 1-deoxy-D-xylulose 5-phosphate/2-C-methyl-D-erythritol 4 phosphate (DOXP/MEP) and fatty acid metabolism pathways, along with the limited competitive advantage of cannabichromenic acid synthetase (CBCAS) compared to other cannabinoid synthases.

View Article and Find Full Text PDF

Ligustilide, a phthalide compound extracted from Umbelliferae plants such as Angelica sinensis and Ligusticum chuanxiong, has been proven to possess various pharmacological activities, such as anti-inflammatory, anti-tumor, anti-atherosclerosis, anti-ischemic stroke injury, and anti-Alzheimer's disease properties. In recent years, it has shown great potential, particularly in the treatment of locomotor system diseases. Studies have shown that ligustilide has significant therapeutic effects on various locomotor system diseases, including osteoporosis, osteoarthritis, femoral head necrosis, osteosarcoma, and muscle aging and injury.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!